News >

Lenvatinib Approved for HCC in Japan

Jason Harris
Published: Friday, Mar 23, 2018

Dr. Roy Baynes
Roy Baynes, MD, PhD
Japan’s Pharmaceuticals and Medical Devices Agency has approved lenvatinib mesylate (Lenvima) for the frontline treatment of patients with unresectable hepatocellular carcinoma (HCC).

Merck and Eisai announced in September 2017 that the US FDA had accepted a supplemental new drug application for frontline lenvatinib in HCC.
Cheng A-L, Finn RS, Qin S, et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2017;35 (suppl; abstr 4001).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x